An open-label, non-randomized, phase I/II study of 44 individuals to investigate the ability of Tc 99m-tilmanocept to identify rheumatoid arthritis (RA) inflamed joints and to identify early RA patients among those with polyarthralgia/polyarthritis

Trial Profile

An open-label, non-randomized, phase I/II study of 44 individuals to investigate the ability of Tc 99m-tilmanocept to identify rheumatoid arthritis (RA) inflamed joints and to identify early RA patients among those with polyarthralgia/polyarthritis

Planning
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 02 Feb 2016 This trial is expected to begin in the second half of 2016, according to a Navidea Biopharmaceuticals media release.
    • 31 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top